Find disease awareness content and relevant supporting materials
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting.
Data analysis of MONALEESA trials shows efficacy and tolerability of Kisqali in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease.-Novartis
Novartis announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali (ribociclib) plus endocrine...
Phase III MONALEESA-2 study shows LEE011 (ribociclib) plus letrozole significantly extended progression-free survival in HR+/HER2- breast cancer- Novartis
Results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib), from Novartis, plus letrozole significantly extended progression-free survival (PFS)...
New data demonstrates only Kisqali offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients.
Novartis announced updated median overall survival (OS) results for Kisqali (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (MONALEESA-3)
The main aim of this study was to evaluate the efficacy and safety of adding ribociclib to fulvestrant in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer.